 Home > Encyclopedia > Valpromide

Valpromide

Valpromide structure

CAS No:
2430-27-5
Formula:
C8H17NO
Chemical Name:
Valpromide
Synonyms:
Pentanamide,2-propyl-;Valeramide,2-propyl-;2-Propylpentanamide;Depamide;2-Propylvaleramide;α-Propylvaleramide;2-Propylpentamide;Depamid;Dipropylacetamide;Di-n-propylacetamide;Valpromide
Categories:
Active Pharmaceutical Ingredients > Nervous System Drugs

Description

Valpromide is an amide derivative of valproic acid and inhibits human epoxide hydrolase.

Valpromide is a fatty amide derived from valproic acid. It has a role as a metabolite, a teratogenic agent and a geroprotector. It derives from a valproic acid.

Valpromide Basic Attributes

Molecular Weight：

143.23

Exact Mass：

143.23

BRN：

1750444

EC Number：

219-394-2

UNII：

RUA6CWU76G

DSSTox ID：

DTXSID1023734

ATC Code：

N - Nervous system

HScode：

2924199090

Characteristics

PSA：

43.1

XLogP3：

2.38840

Appearance：

white to off-white

Density：

0.885g/cm3

Melting Point：

125 °C

Boiling Point：

274.6°C at 760 mmHg

Flash Point：

119.9ºC

Refractive Index：

1.44

Water Solubility：

soluble in chloroform, dimethyl sulfoxideand methanol. Insoluble in water.DMSO: >10mg/mL

Storage Conditions：

room temp

Vapor Pressure：

0.00535mmHg at 25°C

Safety Information

Transport codes：

NONH for all modes of transport

wgk germany：

hazard class code：

safety instructions：

22-36/37

RTECS Number：

YV5965500

Marks：

Precautionary statement(s)：

P264, P270, P301+P312, P330, P501

Hazard Statements：

H302

GHS Classification：

|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P264, P270, P301+P312, P330, and P501|Aggregated GHS information provided by 45 companies from 3 notifications to the ECHA C&L Inventory.

Drug Information

MeSH：

Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)

MeSH Entry Terms：

Depamide

Valpromide Use and Manufacturing

Antiepileptic drugs for the treatment and prevention of many types of epilepsy

Computed Properties

Molecular Weight:143.23
XLogP3:2.1
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:1
Rotatable Bond Count:5
Exact Mass:143.131014166
Monoisotopic Mass:143.131014166
Topological Polar Surface Area:43.1
Heavy Atom Count:10
Complexity:95.4
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Extract from the above information

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Valproamide

Valproamide Tablets
Ingredients	The content of valproamide (C8H17NO) in this product should be 93.0% to 107.0% of the labeled amount.
Indication	1 Drinking alcohol can increase the sedative effect. 2 When general anesthetics or central nervous system depressants are used in combination with valproic acid, the pharmacological effects of the former can be more obvious. 3 When used in combination with anticoagulants such as warfarin or heparin, as well as thrombolytics, the risk of bleeding increases. 4 When used in combination with aspirin or dipyridamole, the bleeding time can be prolonged due to reduced platelet aggregation. 5 When used in combination with phenobarbital, the metabolism of the latter slows down, and the blood concentration increases, thereby increasing the sedative effect and causing drowsiness. 6 When used in combination with primidone, it can also cause an increase in blood concentration and lead to poisoning. If necessary, the dosage of primidone needs to be reduced. 7 When used in combination with clonazepam to prevent absence seizures, there have been reports of a few cases in which absence seizures were induced. 8 When used in combination with phenytoin, there have been reports of cases inducing asterixis. Competition with protein binding can change the blood concentrations of both drugs. Since the concentration of phenytoin changes greatly, it needs to be measured frequently. However, whether the dosage needs to be adjusted depends on the clinical situation and blood drug concentration. 9 When used in combination with carbamazepine, the induction of liver enzymes will accelerate drug metabolism, which can reduce the blood drug concentration and half-life of both drugs. Therefore, the blood drug concentration must be monitored to determine whether the dosage needs to be adjusted. 10 When used in combination with drugs that are toxic to the liver, there is a potential risk of liver poisoning. 11 When used in combination with haloperidol, loxapine, maprotiline, monoamine oxidase inhibitors, phenothiazines, thioxanthenes and tricyclic antidepressants, it can increase the inhibition of the central nervous system, reduce the convulsion threshold and the effect of valproic acid, and the dosage must be adjusted in time to control seizures.
Specifications	0.2g
Manufacturer	Shanxi Lvliang Traditional Chinese Medicine Factory

Valproamide Capsules
Ingredients	The main ingredient of this product is valproamide.
Indication	Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.
Specifications	0.1g
Manufacturer	Shenyang DONGXIN Pharmaceutical Co., Ltd.

See More Related Drugs

Registered Holders

Hunan Dino Pharmaceutical Co., Ltd.

China
Active
Hunan Xiangzhong Pharmaceutical Co., Ltd.

China
Active

Recommended Suppliers of Valpromide

HANGZHOU LEAP CHEM CO., LTD. Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives

Valpromide

CAS No.: 2430-27-5

Content: 99.00%

Inquiry